1. Home
  2. VRXA vs CGC Comparison

VRXA vs CGC Comparison

Compare VRXA & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veraxa Biotech AG Ordinary Shares

VRXA

Veraxa Biotech AG Ordinary Shares

N/A

Current Price

$1.76

Market Cap

390.3M

Sector

Health Care

ML Signal

N/A

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

HOLD

Current Price

$0.92

Market Cap

401.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRXA
CGC
Founded
N/A
N/A
Country
Switzerland
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.3M
401.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
VRXA
CGC
Price
$1.76
$0.92
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
951.5K
2.9M
Earning Date
N/A
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
84.17
EPS
N/A
N/A
Revenue
N/A
$12,759,000.00
Revenue This Year
N/A
$8.27
Revenue Next Year
N/A
$15.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.84
52 Week High
$4.50
$2.38

Technical Indicators

Market Signals
Indicator
VRXA
CGC
Relative Strength Index (RSI) 29.98 41.57
Support Level $1.74 $0.84
Resistance Level $2.29 $1.23
Average True Range (ATR) 0.20 0.04
MACD 0.04 -0.00
Stochastic Oscillator 13.46 31.59

Price Performance

Historical Comparison
VRXA
CGC

About VRXA Veraxa Biotech AG Ordinary Shares

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

Share on Social Networks: